phenethyl isothiocyanate has been researched along with imatinib mesylate in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Artursson, P; Bergström, CA; Hoogstraate, J; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Arlinghaus, RB; Carew, J; Giles, FJ; Huang, P; Keating, MJ; Lu, W; Trachootham, D; Zhang, H | 1 |
| Balayssac, S; Ballot, C; Briand, G; Dammak, A; Dauphin, V; Formstecher, P; Idziorek, T; Jendoubi, M; Joha, S; Jonneaux, A; Kluza, J; Maboudou, P; Malet-Martino, M; Marchetti, P; Quesnel, B | 1 |
| Mukherjee, A; Mukherjee, S; Roy, M; Sarkar, R | 1 |
4 other study(ies) available for phenethyl isothiocyanate and imatinib mesylate
| Article | Year |
|---|---|
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antipsychotic Agents; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Cell Line; Computer Simulation; Cytochrome P-450 Enzyme System; Drug-Related Side Effects and Adverse Reactions; Estradiol; Humans; Insecta; Liver; Models, Molecular; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Pharmaceutical Preparations; Pharmacology; Structure-Activity Relationship | 2008 |
Effective killing of Gleevec-resistant CML cells with T315I mutation by a natural compound PEITC through redox-mediated mechanism.
Topics: Aldehyde Dehydrogenase; Animals; Anticarcinogenic Agents; Antineoplastic Agents; Antioxidants; Apoptosis; Benzamides; Caspase 3; Cells, Cultured; Drug Resistance, Neoplasm; Enzyme Activation; Fusion Proteins, bcr-abl; Glutathione; Humans; Imatinib Mesylate; Immunoblotting; Isothiocyanates; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mutation; Oxidation-Reduction; Piperazines; Precursor Cells, B-Lymphoid; Protein-Tyrosine Kinases; Pyrimidines; Reactive Oxygen Species | 2008 |
Exploiting mitochondrial dysfunction for effective elimination of imatinib-resistant leukemic cells.
Topics: Animals; Arsenic Trioxide; Arsenicals; Benzamides; Cell Death; Cell Line, Tumor; Cell Respiration; Drug Resistance, Neoplasm; Electron Transport; Energy Metabolism; Glucose; Imatinib Mesylate; Isothiocyanates; Leukemia; Mice; Mitochondria; Models, Biological; Oxidative Stress; Oxides; Piperazines; Pyrimidines; Reactive Oxygen Species | 2011 |
Inhibition of crosstalk between Bcr-Abl and PKC signaling by PEITC, augments imatinib sensitivity in chronic myelogenous leukemia cells.
Topics: Anticarcinogenic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Extracellular Signal-Regulated MAP Kinases; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Isothiocyanates; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphocytes; Molecular Targeted Therapy; Phosphorylation; Protein Kinase C; Proto-Oncogene Proteins c-raf | 2015 |